The scale-X bioreactors range and the NevoLine platform represent the next generation of viral manufacturing technologies. These technologies capitalize on the principles of process intensification, automation and chaining to achieve high-performance operations in a miniaturized and integrated process. The design of these technologies offer a range of configurations supporting gene therapies development with a drastic reduction of CAPEX and OPEX as well as final cost of goods. The comprehensive aspect of the scale-X bioreactor range provide to gene therapy developers a solution ensuring batch-to-batch reproducibility allowing a seamless scalability from R&D to commercial phases.